{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:01:04Z","timestamp":1790834464748,"version":"4.1.0"},"reference-count":122,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Ketamine has progressed from solely being an anesthetic agent to a drug of rising clinical and research interest due to its distinctive pharmacological properties. Its dissociative properties and rapid-acting antidepressant effects have made it a prominent area of investigation across many medical and psychiatric applications. This systematic review examines ketamine\u2019s history, mechanisms of action, clinical uses, and significant challenges. A systematic search of PubMed, SCOPUS, PsycINFO, and other sources, generated peer-reviewed publications that addressed the history of ketamine, its pharmacology, clinical applications, recreational use, safety considerations, and societal consequences. Overall, 106 articles were identified for inclusion in this study. At the receptor level, ketamine is an antagonist of NMDA receptors that triggers a number of downstream effects ranging from heightened glutamate transmission, AMPA receptor activation, increased BDNF expression, synaptogenesis, and mTOR pathway signaling. At the network level, it alters activity within large-scale brain circuits including the default mode network, affecting cognition, mood, and perception. Clinically, ketamine is used for anesthesia, treatment-resistant depression, and pain, with off-label uses for PTSD, anxiety disorders, and bipolar disorder. The review also examines current challenges related to ketamine\u2019s recreational use, associated risks, sociocultural factors, and key clinical and ethical considerations, including safety, monitoring, and telehealth prescribing of oral and sublingual formulations. It integrates previously fragmented research from anesthesiology, neuroscience, pharmacology, psychiatry, and public health, consolidates clinical and ethical guidance, identifies critical gaps in current knowledge, and proposes directions for future research.<\/jats:p>","DOI":"10.3389\/fpsyt.2026.1949261","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:41:38Z","timestamp":1790833298000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ketamine in psychiatry: a systematic review of clinical applications, safety considerations, and emerging challenges"],"prefix":"10.3389","volume":"17","author":[{"given":"Matthew M.","family":"Kinney","sequence":"first","affiliation":[{"name":"College of Human Medicine, Michigan State University","place":["East Lansing, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zackary L.","family":"Bowers","sequence":"additional","affiliation":[{"name":"Department of Psychology, Alma College","place":["Alma, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg (London England)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/330604a0","article-title":"The role of NMDA receptors in learning and memory","volume":"330","author":"Collingridge","year":"1987","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1980.10471430","article-title":"History and pharmacology of PCP and PCP-related analogs","volume":"12","author":"Domino","year":"1980","journal-title":"J\u00a0Psychedelic Drugs"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1983.tb11031.x","article-title":"The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate","volume":"79","author":"Anis","year":"1983","journal-title":"Br J Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2020.1854194","article-title":"Ketamine for depression","volume":"33","author":"Jelen","year":"2021","journal-title":"Int Rev Psychiatry (Abingdon England)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2016.00612","article-title":"Ketamine: 50 years of modulating the mind","volume":"10","author":"Li","year":"2016","journal-title":"Front Hum Neurosci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/EJA.0000000000000638","article-title":"History of anaesthesia: The ketamine story \u2013 past, present and future","volume":"34","author":"Mion","year":"2017","journal-title":"Eur J Anaesthesiology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3181ed09a2","article-title":"Taming the ketamine tiger. 1965","volume":"113","author":"Domino","year":"1965","journal-title":"Anesthesiology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109171","article-title":"Ketamine; history and role in anesthetic pharmacology","volume":"216","author":"Hirota","year":"2022","journal-title":"Neuropharmacology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2000.10400244","article-title":"A review of the nonmedical use of ketamine: Use, users and consequences","volume":"32","author":"Jansen","year":"2000","journal-title":"J Psychoact Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1113\/jphysiol.1983.sp014478","article-title":"Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus","volume":"334","author":"Collingridge","year":"1983","journal-title":"J Physiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aer221","article-title":"Ketamine: New uses for an old drug","volume":"107","author":"Hirota","year":"2011","journal-title":"Br J Anaesthesia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17m11634","article-title":"Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression","volume":"79","author":"Albott","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.09.030","article-title":"Early effects predict trajectories of response to esketamine in treatment-resistant depression","volume":"342","author":"Estrade","year":"2023","journal-title":"J Affect Disord"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1268832","article-title":"The Montreal model: An integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression","volume":"14","author":"Garel","year":"2023","journal-title":"Front Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jad.2023.02.151","article-title":"Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study","volume":"330","author":"Leal","year":"2023","journal-title":"J Affect Disord"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2023.79","article-title":"Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial","volume":"223","author":"Loo","year":"2023","journal-title":"Br J Psychiatry: J Ment Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115378","article-title":"Predicting outcome with intranasal esketamine treatment: A machine-learning, three-month study in treatment-resistant depression (ESK-LEARNING)","volume":"327","author":"Pettorruso","year":"2023","journal-title":"Psychiatry Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304145","article-title":"Esketamine nasal spray versus quetiapine for treatment-resistant depression","volume":"389","author":"Reif","year":"2023","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118762073","article-title":"Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders","volume":"32","author":"Glue","year":"2018","journal-title":"J Psychopharmacol (Oxford England)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119874457","article-title":"Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study","volume":"34","author":"Glue","year":"2020","journal-title":"J Psychopharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.194","article-title":"Ketamine for social anxiety disorder: A randomized, placebo-controlled crossover trial","volume":"43","author":"Taylor","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01266-9","article-title":"Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: A double-blind, randomized, placebo-controlled multi-center clinical trial","volume":"47","author":"Abdallah","year":"2022","journal-title":"Neuropsychopharmacology: Off Publ Am Coll Neuropsychopharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.36131\/cnfioritieditore20240102","article-title":"Effectiveness of ketamine for the treatment of post-traumatic stress disorder \u2013 a systematic review and meta-analysis","volume":"21","author":"Almeida","year":"2024","journal-title":"Clin Neuropsychiatry"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.867484","article-title":"Ketamine for bipolar depression: Biochemical, psychotherapeutic, and psychedelic approaches","volume":"13","author":"Bennett","year":"2022","journal-title":"Front Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13060909","article-title":"The role of ketamine in the treatment of bipolar depression: A scoping review","volume":"13","author":"Jawad","year":"2023","journal-title":"Brain Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.10697","article-title":"Considerations on the off-label use of ketamine as a treatment for mood disorders","volume":"318","author":"Wilkinson","year":"2017","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1322752","article-title":"Short-term ketamine use in bipolar depression: A review of the evidence for short-term treatment management","volume":"14","author":"Wilkowska","year":"2023","journal-title":"Front Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m13191","article-title":"Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: Double-blind, randomized study (ASPIRE I)","volume":"81","author":"Fu","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12102283","article-title":"Ketamine, esketamine, and arketamine: Their mechanisms of action and applications in the treatment of depression and alleviation of depressive symptoms","volume":"12","author":"Kawczak","year":"2024","journal-title":"Biomedicines"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am J Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ph16050742","article-title":"Ketamine and the disinhibition hypothesis: Neurotrophic factor-mediated treatment of depression","volume":"16","author":"Borsellino","year":"2023","journal-title":"Pharm (Basel Switzerland)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.neuropharm.2015.07.028","article-title":"Two cellular hypotheses explaining the initiation of ketamine\u2019s antidepressant actions: Direct inhibition and disinhibition","volume":"100","author":"Miller","year":"2016","journal-title":"Neuropharmacology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1316-22.2022","article-title":"NMDA receptor activation-dependent antidepressant-relevant behavioral and synaptic actions of ketamine","volume":"43","author":"Zanos","year":"2023","journal-title":"J Neurosci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6990","DOI":"10.1523\/JNEUROSCI.4998-12.2013","article-title":"Acute suppression of spontaneous neurotransmission drives synaptic potentiation","volume":"33","author":"Nosyreva","year":"2013","journal-title":"J Neuroscience: Off J Soc For Neurosci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41467-019-13809-8","article-title":"Ketamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines","volume":"11","author":"Ali","year":"2020","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2305772120","article-title":"Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments","volume":"120","author":"Krystal","year":"2023","journal-title":"Proc Natl Acad Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109374","article-title":"Role of the mesolimbic dopamine pathway in the antidepressant effects of ketamine","volume":"225","author":"Cardona-Acosta","year":"2023","journal-title":"Neuropharmacology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2001.10400480","article-title":"The nonmedical use of ketamlne, part two: A review of problent use and dependence","volume":"33","author":"Jansen","year":"2001","journal-title":"J Psychoact Drugs"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2018.05.037","article-title":"Pharmacological fMRI: Effects of subanesthetic ketamine on resting-state functional connectivity in the default mode network, salience network, dorsal attention network and executive control network","volume":"19","author":"Mueller","year":"2018","journal-title":"NeuroImage: Clin"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsc.2020.06.015","article-title":"Effects of serial ketamine infusions on corticolimbic functional connectivity in major depression","volume":"6","author":"Vasavada","year":"2021","journal-title":"Biol Psychiatry: Cogn Neurosci Neuroimaging"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.24791","article-title":"Ketamine effects on default mode network activity and vigilance: A randomized, placebo\u2010controlled crossover simultaneous fMRI\/EEG study","volume":"41","author":"Zacharias","year":"2020","journal-title":"Hum Brain Mapp"},{"key":"B45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41398-023-02346-0","article-title":"Association of the delayed changes in glutamate levels and functional connectivity with the immediate network effects of S-ketamine","volume":"13","author":"Danyeli","year":"2023","journal-title":"Transl Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291722001313","article-title":"Anterior default mode network and posterior insular connectivity is predictive of depressive symptom reduction following serial ketamine infusion","volume":"52","author":"Wade","year":"2022","journal-title":"Psychol Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.01.003","article-title":"Ketamine-induced hippocampal functional connectivity alterations associated with clinical remission in major depression","volume":"325","author":"Zhang","year":"2023","journal-title":"J Affect Disord"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1162\/IMAG.a.936","article-title":"Modulation of functional network co-activation pattern dynamics following ketamine treatment in major depression","volume":"3","author":"Taraku","year":"2025","journal-title":"Imaging Neurosci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2016.5","article-title":"Ketamine use in current clinical practice","volume":"37","author":"Gao","year":"2016","journal-title":"Acta Pharmacol Sin"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-021-00232-4","article-title":"Ketamine-50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms","volume":"73","author":"Kohtala","year":"2021","journal-title":"Pharmacol Reports: Pr"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000674","article-title":"Ketamine for pain management","volume":"3","author":"Bell","year":"2018","journal-title":"Pain Rep"},{"key":"B52","unstructured":"Ketamine\n          \n          \n            \n              Rosenbaum\n              SB\n            \n            \n              Gupta\n              V\n            \n            \n              Patel\n              P\n            \n            \n              Palacios\n              JL\n            \n          \n          Treasure Island (FL)\n          StatPearls Publishing\n          Statpearls\n          \n          2026"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13247699","article-title":"The impact of ketamine on outcomes in acute pain management: an umbrella review","volume":"13","author":"Viderman","year":"2024","journal-title":"J Clin Med"},{"key":"B54","article-title":"Intranasal esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant","volume":"44","author":"Bahr","year":"2019","journal-title":"P T A Peer-Reviewed J For Formulary Manage"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001465","article-title":"Esketamine nasal spray for the rapid reduction of depressive symptoms in major depressive disorder with acute suicidal ideation or behavior","volume":"41","author":"Canuso","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.09.141","article-title":"Repeated subcutaneous esketamine on treatment-resistant depression: an open-label dose titration study","volume":"369","author":"Palhano-Fontes","year":"2025","journal-title":"J Affect Disord"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302399","article-title":"Ketamine versus ECT for nonpsychotic treatment-resistant major depression","volume":"388","author":"Anand","year":"2023","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2023.1127863","article-title":"Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches","volume":"4","author":"Batievsky","year":"2023","journal-title":"Front Pain Res (Lausanne Switzerland)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01689-y","article-title":"Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report","volume":"48","author":"Garel","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","article-title":"Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II)","volume":"24","author":"Ionescu","year":"2021","journal-title":"Int J Neuropsychopharmacol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1291077","article-title":"Clinical case report: considerable improvement of severe and difficult-to-treat obsessive-compulsive disorder with comorbid depression under treatment with esketamine and concomitant psychotherapy","volume":"14","author":"Kaltenboeck","year":"2023","journal-title":"Front Psychiatry"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-023-03451-9","article-title":"Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II)","volume":"32","author":"Jamieson","year":"2023","journal-title":"Qual Life Research: Int J Qual Life Aspects Treatment Care Rehabil"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X221116477","article-title":"Evidence for the beneficial effect of ketamine in the treatment of patients with post-traumatic stress disorder: a systematic review and meta-analysis","volume":"42","author":"Albuquerque","year":"2022","journal-title":"J Cereb Blood Flow Metab"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/20008066.2023.2299124","article-title":"So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs","volume":"15","author":"Borgogna","year":"2024","journal-title":"Eur J Psychotraumatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.813103","article-title":"The multivariate effect of ketamine on PTSD: systematic review and meta-analysis","volume":"13","author":"Du","year":"2022","journal-title":"Front Psychiatry"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial","volume":"71","author":"Feder","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apha.2020.05.004","article-title":"The emergence of ketamine as a novel treatment for posttraumatic stress disorder","volume":"89","author":"Feder","year":"2020","journal-title":"Adv Pharmacol (San Diego Calif)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212305","article-title":"Ketamine as treatment for post-traumatic stress disorder: a review","volume":"8","author":"Liriano","year":"2019","journal-title":"Drugs Context"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231154125","article-title":"The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence","volume":"13","author":"Ragnhildstveit","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2022.103723","article-title":"Ketamine attenuates the PTSD-like effect via regulation of glutamatergic signaling in the nucleus accumbens of mice","volume":"120","author":"Asim","year":"2022","journal-title":"Mol Cell Neurosci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3697-9","article-title":"Anxiolytic effects of ketamine in animal models of posttraumatic stress disorder","volume":"232","author":"Zhang","year":"2015","journal-title":"Psychopharmacology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.100","article-title":"Observation of distressed conspecific as a model of emotional trauma generates silent synapses in the prefrontal-amygdala pathway and enhances fear learning, but ketamine abolishes those effects","volume":"40","author":"Ito","year":"2015","journal-title":"Neuropsychopharmacology: Off Publ Am Coll Neuropsychopharmacol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.04.141","article-title":"The effects of ketamine on symptoms of depression and anxiety in real-world care settings: a retrospective controlled analysis","volume":"335","author":"Hietamies","year":"2023","journal-title":"J Affect Disord"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1177\/0269881121998321","article-title":"A qualitative and quantitative account of patient\u2019s experiences of ketamine and its antidepressant properties","volume":"35","author":"Sumner","year":"2021","journal-title":"J Psychopharmacol (Oxford England)"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15374","article-title":"Ketamine treatment for refractory anxiety: a systematic review","volume":"88","author":"Tully","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-025-02889-2","article-title":"Neurophysiological correlates of ketamine-induced dissociative state in bipolar disorder: insights from real-world clinical settings","volume":"30","author":"Agnorelli","year":"2025","journal-title":"Mol Psychiatry"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyab023","article-title":"Ketamine for bipolar depression: a systematic review","volume":"24","author":"Bahji","year":"2021","journal-title":"Int J Neuropsychopharmacol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2026.1777402","article-title":"Ketamine as an NMDA-modulating therapy in bipolar disorder: rationale and evidence","volume":"17","author":"Queissner","year":"2026","journal-title":"Front Psychiatry"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13296","article-title":"Treating bipolar depression with esketamine: safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression","volume":"25","author":"Martinotti","year":"2023","journal-title":"Bipolar Disord"},{"key":"B80","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11920-020-1130-0","article-title":"Bipolar disorder and suicide: a review","volume":"22","author":"Miller","year":"2020","journal-title":"Curr Psychiatry Rep"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231202723","article-title":"Ketamine for bipolar depression: an updated systematic review","volume":"13","author":"Fancy","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/bdi.13284","article-title":"Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression","volume":"25","author":"Fancy","year":"2023","journal-title":"Bipolar Disord"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01586-4","article-title":"Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial","volume":"48","author":"Murphy","year":"2023","journal-title":"Neuropsychopharmacology: Off Publ Am Coll Neuropsychopharmacol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jad.2020.06.020","article-title":"A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression","volume":"275","author":"Zheng","year":"2020","journal-title":"J Affect Disord"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.12.028","article-title":"Poly-club-drug use among gay and bisexual men: a longitudinal analysis","volume":"89","author":"Halkitis","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3109\/14659891.2013.878762","article-title":"Drug use among college and university students: findings from a national survey","volume":"20","author":"Bennett","year":"2015","journal-title":"J Subst Use"},{"key":"B87","volume-title":"Monitoring the Future National Survey Results on Drug Use, 1975\u20132025: Overview and detailed results for secondary school students","author":"Miech","year":"2026"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.01.024","article-title":"Journey through the K-hole: phenomenological aspects of ketamine use","volume":"95","author":"Muetzelfeldt","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107889","article-title":"Trends in drug use among electronic dance music party attendees in New York City, 2016-2019","volume":"209","author":"Palamar","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.28933\/ijprr-2021-07-1505","article-title":"Use of ketamine as a date drug: a systematic scoping review","volume":"52","author":"Dermitzaki","year":"2021","journal-title":"Int J psychol Res Rev"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol Rev"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104001","article-title":"Trends in drug use among nightclub and festival attendees in New York City, 2017-2022","volume":"115","author":"Palamar","year":"2023","journal-title":"Int J Drug Policy"},{"key":"B93","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1001\/jamapsychiatry.2023.1423","article-title":"Trends in illicit ketamine seizures in the US from 2017 to 2022","volume":"80","author":"Palamar","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"B94","volume-title":"World Drug Report 2025","year":"2025"},{"key":"B95","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/02698811241273850","article-title":"Ketamine use in a large global sample: characteristics, patterns of use and emergency medical treatment","volume":"39","author":"Barrios","year":"2025","journal-title":"J Psychopharmacol (Oxford England)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1080\/16066350801983673","article-title":"Sit down to float: the cultural meaning of ketamine use in Hong Kong","volume":"16","author":"Joe-Laidler","year":"2008","journal-title":"Addict Res Theory"},{"key":"B97","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/SAR.S15458","article-title":"To use or not to use: an update on licit and illicit ketamine use","volume":"2","author":"Li","year":"2011","journal-title":"Subst Abuse Rehabil"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2021.306486","article-title":"Trends in ketamine use, exposures, and seizures in the United States up to 2019","volume":"111","author":"Palamar","year":"2021","journal-title":"Am J Public Health"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2018.04.066","article-title":"Ketamine exposure demographics and outcomes over 16 years as reported to US poison centers","volume":"36","author":"Ni","year":"2018","journal-title":"Am J Emergency Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000426","article-title":"Drugs that may cause or exacerbate heart failure: A scientific statement from the American Heart Association","volume":"134","author":"Page","year":"2016","journal-title":"Circulation"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14228","article-title":"Effect of ketamine on cardiovascular function during procedural sedation of adults","volume":"13","author":"Goddard","year":"2021","journal-title":"Cureus"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.10.120","article-title":"A systematic review of the incidence of medical serious adverse events in sub-anesthetic ketamine treatment of psychiatric disorders","volume":"345","author":"Hovda","year":"2024","journal-title":"J Affect Disord"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000003232","article-title":"Safety considerations and risk mitigation strategies for ketamine use: A comprehensive review","volume":"87","author":"Sayad","year":"2025","journal-title":"Ann Med Surg"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3390\/ph17010016","article-title":"Ketamine, an old-new drug: Uses and abuses","volume":"17","author":"Savi\u0107 Vujovi\u0107","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-025-07926-w","article-title":"Association of low-dose ketamine with hallucinations in critically ill patients: A target trial emulation","volume":"51","author":"Serpa Neto","year":"2025","journal-title":"Intensive Care Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am J Psychiatry"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1681060","article-title":"Comparative safety and tolerability of ketamine and esketamine for major depressive disorder: A systematic review and meta-analysis","volume":"16","author":"Guo","year":"2025","journal-title":"Front Pharmacol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2022.795231","article-title":"Brain changes associated with long-term ketamine abuse, a systematic review","volume":"16","author":"Strous","year":"2022","journal-title":"Front Neuroanat"},{"key":"B109","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41398-019-0506-6","article-title":"Differences between ketamine\u2019s short-term and long-term effects on brain circuitry in depression","volume":"9","author":"Gass","year":"2019","journal-title":"Transl Psychiatry"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1503\/jpn.230111","article-title":"Widespread reductions in cortical thickness following ketamine abuse","volume":"49","author":"Tang","year":"2024","journal-title":"J Psychiatry Neuroscience: Jpn"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05873-0","article-title":"Brain volume in chronic ketamine users \u2014 relationship to sub-threshold psychotic symptoms and relevance to schizophrenia","volume":"239","author":"Chesters","year":"2022","journal-title":"Psychopharmacology"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.52965\/001c.38247","article-title":"Ketamine-induced cystitis: A comprehensive review of the urologic effects of this psychoactive drug","volume":"10","author":"Anderson","year":"2022","journal-title":"Health Psychol Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.78422","article-title":"Abdominal pain and dysuria secondary to chronic recreational ketamine use: A case report on K-cramps","volume":"17","author":"Boccio","year":"2025","journal-title":"Cureus"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint15010023","article-title":"Ketamine evolving clinical roles and potential effects with cognitive, motor and driving ability","volume":"15","author":"Edinoff","year":"2023","journal-title":"Neurol Int"},{"key":"B115","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41598-022-04832-9","article-title":"Clinical and behavior characteristics of individuals who used ketamine","volume":"12","author":"Lee","year":"2022","journal-title":"Sci Rep"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2026.210061","article-title":"Treatment and management approaches for ketamine misuse: A systematic review of medical interventions","volume":"191","author":"Mosca","year":"2026","journal-title":"J Subst Use Addict Treat"},{"key":"B117","unstructured":"Risk evaluation and mitigation strategy (REMS) document, SPRAVATO (esketamine)\n          \n          \n          \n          2019"},{"key":"B118","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1001\/jamapsychiatry.2023.4945","article-title":"The rapidly shifting ketamine landscape in the US","volume":"81","author":"Wilkinson","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.25m15809","article-title":"Outpatient ketamine prescribing practices in psychiatry in the United States: A nationwide survey study","volume":"86","author":"Pacilio","year":"2025","journal-title":"J Clin Psychiatry"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1346697","article-title":"Hype or hope? High placebo response in major depression treatment with ketamine and esketamine: A systematic review and meta-analysis","volume":"15","author":"Matsingos","year":"2024","journal-title":"Front Psychiatry"},{"key":"B121","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41398-020-00897-0","article-title":"A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression","volume":"10","author":"Shiroma","year":"2020","journal-title":"Transl Psychiatry"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamapsychiatry.2025.3019","article-title":"Serial ketamine infusions as adjunctive therapy to inpatient care for depression: The KARMA-Dep 2 randomized clinical trial","volume":"82","author":"Jelovac","year":"2025","journal-title":"JAMA Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1949261\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:41:43Z","timestamp":1790833303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1949261\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":122,"alternative-id":["10.3389\/fpsyt.2026.1949261"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1949261","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1949261"}}